


A peer-reviewed, online, open-access journal of stem cells

Diagram of mesenchymal stem cell hierarchy.



Editorial Board

2009-2013

The *World Journal of Stem Cells* Editorial Board consists of 284 members, representing a team of worldwide experts in stem cells research. They are from 28 countries, including Australia (5), Austria (1), Belgium (3), Brazil (2), Canada (7), China (19), Czech Republic (2), Denmark (4), Finland (3), France (5), Germany (14), Hungary (3), India (3), Iran (1), Israel (4), Italy (13), Japan (18), Netherlands (4), Norway (2), Singapore (10), South Korea (15), Spain (6), Sweden (2), Switzerland (3), Turkey (2), United Arab Emirates (1), United Kingdom (15), and United States (117).

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Philippe Bourin, *Toulouse*
Andras Dinnyes, *Godollo*
Umberto Galderisi, *Napoli*
Mikhail G Kolonin, *Houston*
Balazs Sarkadi, *Budapest*

GUEST EDITORIAL BOARD MEMBERS

Ing-Ming Chiu, *Miaoli*
Chie-Pein Chen, *Taipei*
Ju Jyh-Cherng, *Taichung*
Hossein Hosseinkhani, *Taipei*
Steven Shoei-Lung Li, *Kasohsiung*
Tzu-Hao Wang, *Tao-Yuan*

MEMBERS OF THE EDITORIAL BOARD



Australia

Jeremy M Crook, *Melbourne*
Alice Pébay, *Victoria*
Kuldip S Sidhu, *Sydney*
Ernst Wolvetang, *Brisbane*
Xin-Fu Zhou, *Adelaide*



Austria

Ludwig Aigner, *Salzburg*



Belgium

Yves Beguin, *Liege*

Mieke Geens, *Brussels*
Najimi Mustapha, *Brussels*



Brazil

Niels Olsen Saraiva Câmara, *São Paulo*
Naiara Zoccal Saraiva, *Jaboticabal*



Canada

Borhane Annabi, *Montreal*
Rosario Isasi, *Quebec*
Xiao-Yan Jiang, *Vancouver*
Seung U Kim, *Vancouver*
Ren-Ke Li, *Toronto*
Jeffrey A Medin, *Toronto*
Kursad Turksen, *Ottawa*



China

Xiu-Wu Bian, *Chongqing*
Yong Dai, *Shenzhen*
Zhong-Chao Han, *Tianjin*
Zhang Hao, *Beijing*
Anskar YH Leung, *Hong Kong*
Gang Li, *Hong Kong*
Gui-Rong Li, *Hong Kong*
Kai-Yan Liu, *Beijing*
Yi-Jia Lou, *Hangzhou*
Xue-Tao Pei, *Beijing*
Jing-He Tan, *Tan-An*
Jin-Fu Wang, *Hangzhou*
Yun-Hai Zhang, *Hefei*



Czech Republic

Petr Dvorak, *Brno*
Jaroslav Mokry, *Hradec Kralove*



Denmark

Basem M Abdallah, *Odense*
Poul Maddox-Hyttel, *Frederiksberg*
Lin Lin, *Tjele*
Soren Paludan Sheikh, *Odense*



Finland

Jukka Partanen, *Helsinki*
Petri Salven, *Helsinki*
Heli Skottman, *Tampere*



France

Alain Chapel, *Paris*
Gwendal Lazennec, *Montpellier*
Muriel Perron, *Cedex*
Xavier Thomas, *Lyon*



Germany

James Adjaye, *Berlin*
Christian Buske, *Ulm*
Denis Corbeil, *Dresden*
Frank Edenhofer, *Bonn*
Ursula Margarethe Gehling, *Langen*
Eric Gottwald, *Eggenstein-Leopoldshafen*
Jorg Kleeff, *Munich*
Gesine Kögler, *Düsseldorf*
Nan Ma, *Rostock*
Ulrich Martin, *Hannover*
Heinrich Sauer, *Giessen*
Richard Schäfer, *Tübingen*
Sonja Schrepfer, *Hamburg*
Wolfgang Wagner, *Aachen*

**Hungary**Ferenc Uher, *Budapest***India**Gurudutta U Gangenahalli, *Delhi*
Asok Mukhopadhyay, *New Delhi*
Anjali Suhas Shiras, *Maharashtra***Iran**Masoud Soleimani, *Tehran***Israel**Zeev Blumenfeld, *Haifa*
Rachel Sarig, *Rehovot*
Avichai Shimoni, *Tel-Hashomer*
Shimon Slavin, *Tel Aviv***Italy**Carlo Alberto Beltrami, *Udine*
Clotilde Castaldo, *Naples*
Carmelo Carlo-Stella, *Milano*
Massimo Dominici, *Modena*
Stefania Filos, *Naples*
Angela Gritti, *Milano*
Roberta Morosetti, *Rome*
Felicita Pedata, *Florence*
Anna Chiara Piscaglia, *Rome*
Stefano Pluchino, *Milan*
Caterina AM La Porta, *Milan*
Domenico Ribatti, *Bari***Japan**Tomoki Aoyama, *Kyoto*
Susumu Ikehara, *Osaka*
Taro Matsumoto, *Tokyo*
Yuko Miyagoe-Suzuki, *Tokyo*
Hiroyuki Miyoshi, *Tsukuba*
Takashi Nagasawa, *Kyoto*
Tetsuhiro Niidome, *Kyoto*
Toshio Nikaido, *Toyama*
Kohzo Nakayama, *Nagano*
Tsukasa Ohmori, *Tochigi*
Caterina AM La Porta, *Milan*
Kumiko Saeki, *Tokyo*
Kazunobu Sawamoto, *Aichi*
Mikiko C Siomi, *Tokyo*
Yoshiaki Sonoda, *Osaka*
Takashi Tada, *Kyoto*
Kotaro Yoshimura, *Tokyo*
Louis Yuge, *Hiroshima***Netherlands**Dirk Gijsbert de Rooij, *Amsterdam*Christine Mummery, *Leiden*
Frank JT Staal, *Leiden*
Marten Piet Smidt, *Utrecht***Norway**Brynjar Foss, *Stavanger*
Berit Bølge Tysnes, *Bergen***Singapore**Yu Cai, *Research Link*
Tong Cao, *Singapore*
Jerry Chan, *Singapore*
Gavin Stewart Dawe, *Medical Drive*
Chan Kwok-Keung Ken, *Singapore*
Chan Woon Khiong, *Singapore*
Steve KW Oh, *Singapore*
Seeram Ramakrishna, *Singapore*
Herbert Schwarz, *Singapore*
Shu Wang, *Biopolis Way***South Korea**Jong Wook Chang, *Seoul*
Chong-Su Cho, *Seoul*
Ssang-Goo Cho, *Seoul*
Ho Jae Han, *Gwangju*
Ki-Chul Hwang, *Seoul*
Kyung-Sun Kang, *Seoul*
Haekwon Kim, *Seoul*
Hoeon Kim, *Daejeon*
Mee Kum Kim, *Seoul*
Yoon Jun Kim, *Seoul*
Soo-Hong Lee, *Seoul*
Dae-Sik Lim, *Daejeon*
Byung Soon Park, *Seoul*
Sun U Song, *Incheon*
Seung Kwon You, *Seoul***Spain**Fernando Cobo, *Granada*
Sabrina C Desbordes, *Barcelona*
Marta Muñoz Llamosas, *España*
Maria P De Miguel, *Madrid*
María Dolores Miñana, *Valencia*
Felipe Prosper, *Navarra***Sweden**M Quamrul Islam, *Linköping*
Stefan Karlsson, *Lund***Switzerland**Thomas Daikeler, *Basel*
Sabrina Mattoli, *Basel*
Arnaud Scherberich, *Basel***Turkey**Alp CAN, *Ankara*
Berna Arda, *Ankara***United Arab Emirates**Sherif M Karam, *Al-Ain***United Kingdom**Dominique Bonnet, *London*
Kristin Mary Braun, *London*
Wei Cui, *London*
David C Hay, *Edinburgh*
Wael Kafienah, *Bristol*
Francis L Martin, *Lancaster*
Mike Modo, *London*
Donald Palmer, *London*
Dame Julia Polak, *London*
James Alexander Ross, *Edinburgh*
Alastair James Sloan, *Cardiff*
Virginie Sottile, *Nottingham*
Hong Wan, *London*
He-Ping Xu, *Aberdeen*
Rike Zietlow, *Cardiff***United States**Gregor Barr Adams, *Los Angeles*
Kinji Asahina, *Los Angeles*
Craig S Atwood, *Madison*
Debabrata Banerjee, *New Brunswick*
Aline M Betancourt, *New Orleans*
Surinder Kumar Batra, *Omaha*
Bruce Alan Bunnell, *New Orleans*
Jason A Burdick, *Philadelphia*
Anthony WS Chan, *Atlanta*
Rebecca J Chan, *Indianapolis*
G Rasul Chaudhry, *Rochester*
Jonathan Donald Chesnut, *Carlsbad*
Herman S Cheung, *Coral Gables*
Kent W Christopherson II, *Chicago*
David Wade Clapp, *Indianapolis*
Rubin Clinton, *New York*
Claudius Conrad, *Boston*
Charles Samuel Cox, *Houston*
Marcos de Lima, *Houston*
Douglas C Dean, *Louisville*
Goberdhan Dimri, *Evanston*
David Dingli, *Rochester*
Fu-Liang Du, *Vernon*
Todd Evans, *New York*
Toshihiko Ezashi, *Columbia*
Vincent Falanga, *Alternate*
Ira J Fox, *Pittsburgh*
Markus Frank, *Boston*
Sanga Gehmert, *Houston*
Yong-Jian Geng, *Houston*
Joseph C Glorioso, *Pittsburgh*
Kristbjorn Orri Gudmundsson, *Frederick*
Yan-Lin Guo, *Hattiesburg*
Tong-Chuan He, *Chicago*
Lorraine Iacovitti, *Philadelphia*
Kunlin Jin, *Novato*

Michael R King, *Ithaca*
Uma Lakshminpathy, *Carlsbad*
Hillard Michael Lazarus, *Shaker Heights*
Techung Lee, *Buffalo*
Robert C Miller, *Rochester*
Tao-Sheng Li, *Los Angeles*
Xiao-Nan Li, *Houston*
Ching-Shwun Lin, *San Francisco*
P Charles Lin, *Nashville*
Su-Ling Liu, *Ann Arbor*
Aurelio Lorico, *Las Vegas*
Jean-Pierre Louboutin, *Philadelphia*
Bing-Wei Lu, *Stanford*
Qing Richard Lu, *Dallas*
Nadya L Lumelsky, *Bethesda*
Hong-Bo R Luo, *Boston*
Hinh Ly, *Atlanta*
Teng Ma, *Tallahassee*
Kenneth Maiese, *Detroit*
Robert L Mauck, *Philadelphia*
Glenn Edwards Mcgee, *New York*
Murielle Mimeault, *Omaha*
Guo-Li Ming, *Baltimore*
Masato Nakafuku, *Cincinnati*
Christopher Niyibizi, *Hershey*
Seh-Hoon Oh, *Gainesville*
Frank Pajonk, *Los Angeles*

Gregory M Pastores, *New York*
Derek A Persons, *Memphis*
Donald G Phinney, *Florida*
Donald George Phinney, *New Orleans*
Dimitris G Placantonakis, *New York*
George E Plopper, *Troy*
Derek Radisky, *Jacksonville*
Murugan Ramalingam, *Gaithersburg*
Pranela Rameshwar, *Newark*
Jeremy N Rich, *Cleveland*
Angie Rizzino, *Omaha*
Paul Ronald Sanberg, *Tampa*
Gerald Phillip Schatten, *Pittsburgh*
Ashok Kumar Shetty, *Durham*
Igor I Slukvin, *Madison*
Shay Soker, *Winston-Salem*
Hong-Jun Song, *Baltimore*
Kenichi Tamama, *Columbus*
Dean G Tang, *Smithville*
Hugh S Taylor, *New Haven*
Jonathan L Tilly, *Boston*
Jakub Tolar, *Minneapolis*
Deryl Troyer, *Manhattan*
Scheffer Chuei-Goong Tseng, *Miami*
Lyuba Varticovski, *Bethesda*
Tandis Vazin, *Berkeley*
Kent E Vrana, *Hershey*

Lyuba Varticovski, *Bethesda*
Qi Wan, *Reno*
Charles Wang, *Los Angeles*
Guo-Shun Wang, *New Orleans*
Zack Z Wang, *Scarborough*
David Warburton, *Los Angeles*
Li-Na Wei, *Jackson Hall*
Andre Van Wijnen, *Worcester*
Marc Adrian Williams, *Rochester*
Joseph C Wu, *Stanford*
Li-Zi Wu, *Gainesville*
Sean M Wu, *Boston*
Yan Xu, *Pittsburgh*
Jun Yan, *Louisville*
Jing Yang, *Orange*
Li-Jun Yang, *Florida*
Phillip Chung-Ming Yang, *Stanford*
Pampee Paul Young, *Nashville*
Hong Yu, *Miami*
Seong-Woon Yu, *East Lansing*
Xian-Min Zeng, *Novato*
Bao-Hong Zhang, *Greenville*
Ying Zhang, *Baltimore*
Xue-Sheng Zheng, *Massachusetts*
X Long Zheng, *Philadelphia*
John F Zhong, *Los Angeles*

Contents

Bimonthly Volume 2 Number 1 February 26, 2010

EDITORIAL

- 1 Advances in stem cell therapy for the lower urinary tract
Lin CS

REVIEW

- 5 The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents
Galderisi U, Giordano A, Paggi MG

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Stem Cells*

APPENDIX I Meetings
 I-IV Instructions to authors

ABOUT COVER Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents.
World J Stem Cells 2010; 2(1): 5-12
<http://www.wjgnet.com/1948-0210/full/v2/i1/5.htm>

AIM AND SCOPE *World Journal of Stem Cells* (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), renamed from Stem Cells Review Letters, is a bimonthly open-access (OA) peer-reviewed journal supported by an editorial board consisting of 284 experts in stem cell research from 28 countries.
 The major task of *WJSC* is to rapidly report original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including embryonic stem cells, neural stem cells, hematopoietic stem cells, mesenchymal stem cells, tissue-specific stem cells, cancer stem cells, the stem cell niche, stem cell genomics and proteomics, and translational and clinical research. In a word, papers published in *WJSC* will cover the biology, culture, and differentiation of stem cells from all stages of development from germ cell to embryo and adult.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Na Liu*
 Responsible Electronic Editor: *Chuan Yang*
 Proofing Editor-in-Chief: *Lian-Sheng Ma*
 Responsible Science Editor: *Lai-Fu Li*
 Proofing Editorial Office Director: *Lai-Fu Li*

NAME OF JOURNAL
World Journal of Stem Cells

LAUNCH DATE
 December 31, 2009

SPONSOR
 Beijing Baishideng BioMed Scientific Co., Ltd.,
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: 0086-10-8538-1892
 Fax: 0086-10-8538-1893
 E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

EDITING
 Editorial Board of *World Journal of Stem Cells*,
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: +0086-10-8538-1891
 Fax: +0086-10-8538-1893
 E-mail: wjsc@wjgnet.com
<http://www.wjgnet.com>

PUBLISHING
 Beijing Baishideng BioMed Scientific Co., Ltd.,
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: 0086-10-8538-1892

Fax: 0086-10-8538-1893
 E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

SUBSCRIPTION
 Beijing Baishideng BioMed Scientific Co., Ltd.,
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: 0086-10-8538-1892
 Fax: 0086-10-8538-1893
 E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

ONLINE SUBSCRIPTION
 One-Year Price 216.00 USD

PUBLICATION DATE
 February 26, 2010

CSSN
 ISSN 1948-0210 (online)

PRESIDENT AND EDITOR-IN-CHIEF
 Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF
 Philippe Bourin, *Toulouse*
 Andras Dinnyes, *Godollo*
 Umberto Galderisi, *Napoli*
 Mikhail G Kolonin, *Houston*
 Balazs Sarkadi, *Budapest*

EDITORIAL OFFICE
 Lai-Fu Li, Director
World Journal of Stem Cells
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: 0086-10-8538-1891
 Fax: 0086-10-8538-1893
 E-mail: wjsc@wjgnet.com
<http://www.wjgnet.com>

COPYRIGHT
 © 2010 Baishideng. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of Baishideng. Author are required to grant *World Journal of Stem Cells* an exclusive license to publish.

SPECIAL STATEMENT
 All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
 Full instructions are available online at <http://www.wjgnet.com/1948-0210/index.htm>. If you do not have web access please contact the editorial office.

ONLINE SUBMISSION
<http://www.wjgnet.com/1948-0210office>

Advances in stem cell therapy for the lower urinary tract

Ching-Shwun Lin

Ching-Shwun Lin, Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA 94143-0738, United States

Author contributions: Lin CS is the sole contributor to this Editorial.

Correspondence to: Ching-Shwun Lin, PhD, Professor, Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA 94143-0738, United States. clin@urology.ucsf.edu
Telephone: +1-415-4763800 Fax: +1-415-4763803

Received: November 19, 2009 Revised: January 6, 2010

Accepted: January 13, 2010

Published online: February 26, 2010

Abstract

Lower urinary tract diseases are emotionally and financially burdensome to the individual and society. Current treatments are ineffective or symptomatic. Conversely, stem cells (SCs) are regenerative and may offer long-term solutions. Among the different types of SCs, bone marrow SCs (BMSCs) and skeletal muscle-derived SCs (SkMSCs) have received the most attention in pre-clinical and clinical trial studies concerning the lower urinary tract. In particular, clinical trials with SkMSCs for stress urinary incontinence have demonstrated impressive efficacy. However, both SkMSCs and BMSCs are difficult to obtain in quantity and therefore neither is optimal for the eventual implementation of SC therapy. On the other hand, adipose tissue-derived SCs (ADSCs) can be easily and abundantly obtained from "discarded" adipose tissue. Moreover, in several head-on comparison studies, ADSCs have demonstrated equal or superior therapeutic potential compared to BMSCs. Therefore, across several different medical disciplines, including urology, ADSC research is gaining wide attention. For the regeneration of bladder tissues, possible differentiation of ADSCs into bladder smooth muscle and epithelial cells has been demonstrated. For the treatment of bladder diseases, specifically hyperlipidemia and associated overactive bladder, ADSCs have also demonstrated efficacy. For the treatment of urethral sphincter dysfunction associated with birth trauma and hormonal deficiency,

ADSC therapy was also beneficial. Finally, ADSCs were able to restore erectile function in various types of erectile dysfunction (ED), including those associated with diabetes, hyperlipidemia, and nerve injuries. Thus, ADSCs have demonstrated remarkable therapeutic potentials for the lower urinary tract.

© 2010 Baishideng. All rights reserved.

Key words: Stem cells; Bladder; Urethra; Penis; Urinary incontinence; Erectile dysfunction

Peer reviewer: Alain Chapel, PhD, IRSN/DRPH/SRBE, BP17 926262, Far, France

Lin CS. Advances in stem cell therapy for the lower urinary tract. *World J Stem Cells* 2010; 2(1): 1-4 Available from: URL: <http://www.wjgnet.com/1948-0210/full/v2/i1/1.htm> DOI: <http://dx.doi.org/10.4252/wjsc.v2.i1.1>

INTRODUCTION

The lower urinary tract can become dysfunctional due to aging, diabetes, obesity, and other factors. Although usually not life-threatening, problems of the urinary bladder, urethra, and penis can severely impact the patient's quality of life and impose heavy financial burdens on the individual and society. Current treatments for these diseases are ineffective or invariably temporary, symptomatic, and/or accompanied by adverse side effects. Therefore, stem cells (SCs), owing to their regenerative capacity, are considered promising curative agents for these urological diseases.

In this regard, several kinds of SCs have been studied, including embryonic SCs (ESCs), bone marrow SCs (BMSCs), skeletal muscle-derived SCs (SkMSCs), adipose tissue-derived SCs (ADSCs), and amniotic fluid SCs (AFSCs). While ESCs and BMSCs, owing to their earlier discoveries, are the best studied SCs in most medical disciplines, it is SkMSC research that has advanced ahead of other kinds of SC research and these cells have been used in clinical trials in urological research. However, ADSCs are

much easier than SkMSCs to obtain in quantity and have been shown to possess properties very similar to BMSCs. In several animal studies that are recently published or in press, ADSCs have demonstrated efficacy in the treatment of various types of dysfunctional bladder, urethra, and penis^[1-4]. For detailed discussions on the general properties of ADSCs and other SC types mentioned above, several review articles are available^[5-9]. In this editorial article, attention is focused on SC clinical and pre-clinical applications; it is organized into three sections according to diseases of the bladder, urethra, and penis.

BLADDER

SC research has been conducted for two situations regarding the bladder. One is treatment of urge urinary incontinence (UUI), which is defined as the involuntary loss of urine associated with a strong sensation to void. Many risk factors are associated with UUI, one of which is hyperlipidemia. In a rat model of hyperlipidemia-associated UUI, ADSCs have recently been shown to improve continence^[1]. Administration of ADSCs through intra-bladder injection or tail vein injection was equally effective. Functional improvement was accompanied with tissue improvement, as treated subjects showed enhanced muscle, vascular and nerve contents compared to controls. In preclinical studies of UUI related to diabetes or birth trauma/menopause, ADSC treatment was also effective (data not published).

The other is bladder restoration or augmentation; that is, the need to replace part of or the entire bladder or to increase the size of the bladder. Bladder restoration or augmentation requires tissue engineering to recreate the native bladder milieu. Currently, the favored approach involves seeding a scaffold, usually an acellular matrix, with autologous bladder smooth muscle and epithelial cells. However, a significant drawback of this approach is the risk of reintroducing the pathologic condition (e.g. cancer) to the engineered tissue. For this and several other reasons, SCs are considered as an ideal alternative to using autologous bladder cells. To this end, acellular matrix seeded with embryoid body-derived SCs has been shown to facilitate the complete regeneration of partially cystectomized bladder^[10]. However, whether the seeded cells had differentiated into bladder cells remained unclear. On the other hand, possible differentiation of SkMSCs into bladder smooth muscle cells (SMCs) has been reported^[11], and this was followed by a related report demonstrating contractility of seeded SkMSCs^[12].

Possible differentiation of BMSCs into bladder SMCs has also been reported in several studies^[13-17]. One of these studies^[13] showed that BMSCs or AFSCs transplanted into cryo-injured rat bladder underwent limited SMC differentiation. Although differentiation of ADSCs into bladder SMCs has been reported^[18,19], we found this to be a rare occurrence and suggested that ADSC therapeutic effects were principally mediated by paracrine actions^[1]. Urothelial differentiation of SCs is expected to be more

difficult than SMC differentiation because the urothelial cells are highly specialized entities both in structure and in functionality; and this adds to what is already a challenging task of transdifferentiating from the mesenchymal to the epithelial lineage. However, despite these tremendous odds, a recent study showed that ADSCs were able to express certain urothelial markers when co-cultured with preexisting urothelial cells^[20]. Interestingly, this probable urothelial differentiation of ADSCs required direct cell-cell contact with the pre-existing urothelial cells.

Thus, it appears that conventional strategies, such as growth factors and gene transfer, will not be sufficient to direct differentiation of ADSCs, and possibly other SCs, into functional urothelial cells. Nevertheless, this latest study reiterates the remarkable differentiation potential of ADSCs (at least, *in vitro*) and hopefully, with continued research efforts, it may be possible someday to convert ADSCs into a useful urothelium.

URETHRA

The urethra is the most studied urological organ as far as SC therapy is concerned. This is perhaps due to the assumption that restoration of the urethral musculature alone would be sufficient to correct the most frequently encountered urethral problem; i.e. sphincter deficiency, which manifests symptomatically as stress urinary incontinence (SUI). While primarily a female concern, because of pregnancy and parturition-associated injuries to the urethra, SUI can also occur in men due to prostate surgeries.

Initial cell-based experimental therapy for SUI involved the injection of autologous skeletal myoblasts into the vicinity of the urethral sphincter^[21]. It then progressed to substituting myoblasts with SkMSCs, and eventually several clinical trials with SkMSCs were conducted, resulting in 3 publications from an Austrian group^[22-24] and one from an American research team^[25]. Although clinical outcomes of these studies are generally favorable, a clear disadvantage of SkMSCs is the requirement for complicated isolation procedures and long-term culturing, as skeletal muscle cannot be practically obtained in quantity from the patient.

Application of other types of SCs, including BMSCs, may also pose the same problem if cells are to be employed autologously. The only exception is ADSCs because, in our increasingly obese society, adipose tissue is often considered dispensable, and the commonly performed liposuction procedure is capable of safely isolating large quantities of adipose tissue. Furthermore, it has been shown that ADSCs can be isolated and injected back into the same patients for successful breast augmentation in approximately 4 h^[26]; therefore, it is reasonable to expect that ADSCs can be used to treat the much smaller urethra on a same-day basis without the need for culturing. Thus, as a first step toward this goal, we recently demonstrated the efficacy of ADSCs in treating SUI in an animal model^[2]. We showed that tail vein injection of ADSCs was equally effective as intra-urethral injection, thus pointing to the possibility of using the convenient

intravenous route for administering ADSCs clinically. We also showed that ADSC treatment restored not only the cellular (SMC) but also the extracellular (elastin) components in the experimentally injured rat urethra. Thus, it appears that ADSCs have the potential to “cure” SUI by correcting the underlying cellular and extracellular defects in the injured urethral sphincter.

PENIS

Phosphodiesterase type-5 (PDE5) inhibitors are currently the first-line treatment of choice for men with erectile dysfunction (ED). However, PDE5 inhibitors are strictly contraindicated in men taking nitrate therapy and are known to cause a variety of adverse side effects that may reduce their suitability for some patients. More importantly, PDE5 inhibitors are ineffective in treating certain types of ED including those associated with diabetes, hyperlipidemia, and surgery-induced penile nerve injuries. As such, alternative treatments, particularly those that can treat the underlying disease process of ED, would be preferable to currently available interventions.

In this regard, one of the strategies currently being evaluated is stem cell therapy. In 2003, Deng *et al*^[27] showed that BMSCs transduced with endothelial nitric oxide synthase (eNOS) were able to improve erectile function in aged rats. In 2004, Bochinski *et al*^[28] showed that ESC transduced with brain-derived neurotrophic factor improved erectile function in a rat model of post-prostatectomy ED. In 2007, Bivalacqua *et al*^[29] demonstrated that BMSCs alone or transduced with eNOS were able to reverse age-associated ED. Also in 2007, Song *et al*^[30] showed that immortalized human BMSCs (by v-myc transfection) transplanted into rat corpus cavernosum could differentiate into endothelial cells and SMCs. In 2008, Fall *et al*^[31] reported that intracavernous injection of BMSCs improved erectile function in a rat model of post-prostatectomy ED. Also, in 2008, Nolzco *et al*^[32] indicated that intracavernous injection of SkMSCs could restore cavernous SMCs and erectile function in aged rats.

The therapeutic potential of ADSCs for ED was recently reported^[33]. Specifically, we showed that *in vitro* endothelial differentiation of ADSC, mediated by FGF2 and ADSC injected into rat penis, appeared to have differentiated into endothelial cells. Since the cavernous endothelium plays a key role in penile erection and is often damaged in disease processes such as diabetes and hyperlipidemia, it is important that we provide further evidence that ADSC can restore endothelial function in the erectile tissue. To this end, we recently demonstrated the efficacy of ADSCs to treat diabetes and hyperlipidemia-associated ED, respectively^[3,4]. In both studies, functional improvements were accompanied with restoration of the crucial endothelial and neural components in the penis, suggesting the curative prospect of ADSC treatment. In another study of postprostatectomy ED, ADSCs were also effective in restoring the damaged nerves and improving erectile function (data not published). Thus, it appears that ADSC has the potential to treat various forms of ED.

CONCLUDING REMARKS

Several types of SCs have been investigated for the treatment of lower urinary tract diseases. Specifically, BMSCs, SkMSCs, and AFSCs have been tested in preclinical studies for bladder augmentation and detrusor regeneration with various degrees of efficacy. In addition, clinical trials on SkMSC therapy for SUI have produced favorable outcomes. Moreover, ESCs, BMSCs, and SkMSCs were shown to improve erectile function in animal models of age-related and postprostatectomy ED. However, the afore-mentioned SC types suffer from ethical and/or availability concerns. Conversely, ADSCs are an abundant cell source and have been shown to possess similar biological properties and therapeutic potentials as BMSCs. In particular, ADSCs seemed able to, at least partially, differentiate into the complex and highly specialized urothelial cells. In regard to ADSC therapeutic potential for lower urinary tract diseases, recent pre-clinical studies have produced favorable results. Specifically, ADSCs were able to restore near normal function in animal models of hyperlipidemia-associated overactive bladder, birth trauma-induced SUI, hyperlipidemia-associated ED, and diabetic ED.

Despite these advances, however, challenges facing urology and other medical disciplines are numerous. In regard to ESC, ethical and tumorigenicity concerns are paramount. In regard to adult SCs, can they really transdifferentiate *in vivo* and thereby replenish the degenerated tissue? Or, do they simply secrete certain growth factors that help the host tissue to regenerate? More importantly, how “translatable” are pre-clinical studies? That is, can animal models, which are designed to display a specific human disease entity, faithfully represent human patients who are prone to having co-morbidity? In any event, answers to these questions are probably easier to find in urological research than in other disciplines because the lower urinary tract organs are relatively simple in structure and are easily accessible. Thus, advances in SC therapy for the lower urinary tract are the forerunners of SC research.

REFERENCES

- 1 **Huang YC**, Shindel AW, Ning H, Lin G, Harraz AM, Wang G, Garcia M, Lue TF, Lin CS. Adipose Derived Stem Cells Ameliorate Hyperlipidemia Associated Detrusor Overactivity in a Rat Model. *J Urol*. 2010; **183**: 1232-1240
- 2 **Lin G**, Wang G, Banie L, Ning H, Shindel AW, Fandel TM, Lue TF, Lin CS. Treatment of stress urinary incontinence with adipose tissue-derived stem cells. *Cytotherapy* 2010; **12**: 88-95
- 3 **Garcia MM**, Fandel TM, Lin G, Shindel AW, Banie L, Lin CS, Lue TF. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. *J Sex Med* 2010; **7**: 89-98
- 4 **Huang YC**, Ning H, Shindel AW, Fandel TM, Lin G, Harraz AM, Lue TF, Lin CS. The Effect of Intracavernous Injection of Adipose Tissue-Derived Stem Cells on Hyperlipidemia-Associated Erectile Dysfunction in a Rat Model. *J Sex Med* 2010; [Epub ahead of print]
- 5 **Gregory CA**, Prockop DJ, Spees JL. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. *Exp Cell Res* 2005; **306**: 330-335

- 6 **Usas A**, Huard J. Muscle-derived stem cells for tissue engineering and regenerative therapy. *Biomaterials* 2007; **28**: 5401-5406
- 7 **Deb KD**, Sarda K. Human embryonic stem cells: preclinical perspectives. *J Transl Med* 2008; **6**: 7
- 8 **Siegel N**, Rosner M, Hanneder M, Freilinger A, Hengstschlager M. Human amniotic fluid stem cells: a new perspective. *Amino Acids* 2008; **35**: 291-293
- 9 **Lin CS**, Xin ZC, Deng CH, Ning H, Lin G, Fue TL. Defining adipose-tissue-derived stem cells in tissue and in culture. *Histol Histopathol* 2010; In press
- 10 **Frimberger D**, Morales N, Shablott M, Gearhart JD, Gearhart JP, Lakshmanan Y. Human embryoid body-derived stem cells in bladder regeneration using rodent model. *Urology* 2005; **65**: 827-832
- 11 **Yokoyama T**, Huard J, Pruchnic R, Yoshimura N, Qu Z, Cao B, de Groat WC, Kumon H, Chancellor MB. Muscle-derived cell transplantation and differentiation into lower urinary tract smooth muscle. *Urology* 2001; **57**: 826-831
- 12 **Lu SH**, Cannon TW, Chermanski C, Pruchnic R, Somogyi G, Sacks M, de Groat WC, Huard J, Chancellor MB. Muscle-derived stem cells seeded into acellular scaffolds develop calcium-dependent contractile activity that is modulated by nicotinic receptors. *Urology* 2003; **61**: 1285-1291
- 13 **Kanematsu A**, Yamamoto S, Iwai-Kanai E, Kanatani I, Imamura M, Adam RM, Tabata Y, Ogawa O. Induction of smooth muscle cell-like phenotype in marrow-derived cells among regenerating urinary bladder smooth muscle cells. *Am J Pathol* 2005; **166**: 565-573
- 14 **Zhang Y**, Lin HK, Frimberger D, Epstein RB, Kropp BP. Growth of bone marrow stromal cells on small intestinal submucosa: an alternative cell source for tissue engineered bladder. *BJU Int* 2005; **96**: 1120-1125
- 15 **De Coppi P**, Callegari A, Chiavegato A, Gasparotto L, Piccoli M, Taiani J, Pozzobon M, Boldrin L, Okabe M, Cozzi E, Atala A, Gamba P, Sartore S. Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. *J Urol* 2007; **177**: 369-376
- 16 **Shukla D**, Box GN, Edwards RA, Tyson DR. Bone marrow stem cells for urologic tissue engineering. *World J Urol* 2008; **26**: 341-349
- 17 **Tian H**, Bharadwaj S, Liu Y, Ma H, Ma PX, Atala A, Zhang Y. Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering. *Biomaterials* 2010; **31**: 870-877
- 18 **Rodrguez LV**, Alfonso Z, Zhang R, Leung J, Wu B, Ignarro LJ. Clonogenic multipotent stem cells in human adipose tissue differentiate into functional smooth muscle cells. *Proc Natl Acad Sci USA* 2006; **103**: 12167-12172
- 19 **Jack GS**, Zhang R, Lee M, Xu Y, Wu BM, Rodrguez LV. Urinary bladder smooth muscle engineered from adipose stem cells and a three dimensional synthetic composite. *Biomaterials* 2009; **30**: 3259-3270
- 20 **Liu J**, Huang J, Lin T, Zhang C, Yin X. Cell-to-cell contact induces human adipose tissue-derived stromal cells to differentiate into urothelium-like cells in vitro. *Biochem Biophys Res Commun* 2009; **390**: 931-936
- 21 **Yokoyama T**, Huard J, Chancellor MB. Myoblast therapy for stress urinary incontinence and bladder dysfunction. *World J Urol* 2000; **18**: 56-61
- 22 **Mitterberger M**, Marksteiner R, Margreiter E, Pinggera GM, Colleselli D, Frauscher F, Ulmer H, Fussenegger M, Bartsch G, Strasser H. Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients. *BJU Int* 2007; **100**: 1081-1085
- 23 **Strasser H**, Marksteiner R, Margreiter E, Mitterberger M, Pinggera GM, Frauscher F, Fussenegger M, Kofler K, Bartsch G. Transurethral ultrasonography-guided injection of adult autologous stem cells versus transurethral endoscopic injection of collagen in treatment of urinary incontinence. *World J Urol* 2007; **25**: 385-392
- 24 **Mitterberger M**, Pinggera GM, Marksteiner R, Margreiter E, Fussenegger M, Frauscher F, Ulmer H, Hering S, Bartsch G, Strasser H. Adult stem cell therapy of female stress urinary incontinence. *Eur Urol* 2008; **53**: 169-175
- 25 **Carr LK**, Steele D, Steele S, Wagner D, Pruchnic R, Jankowski R, Erickson J, Huard J, Chancellor MB. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct* 2008; **19**: 881-883
- 26 **Yoshimura K**, Sato K, Aoi N, Kurita M, Hirohi T, Harii K. Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. *Aesthetic Plast Surg* 2008; **32**: 48-55; discussion 56-57
- 27 **Deng W**, Bivalacqua TJ, Chattergoon NN, Hyman AL, Jeter JR Jr, Kadowitz PJ. Adenoviral gene transfer of eNOS: high-level expression in ex vivo expanded marrow stromal cells. *Am J Physiol Cell Physiol* 2003; **285**: C1322-C1329
- 28 **Bochinski D**, Lin GT, Nunes L, Carrion R, Rahman N, Lin CS, Lue TF. The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. *BJU Int* 2004; **94**: 904-909
- 29 **Bivalacqua TJ**, Deng W, Kendirci M, Usta MF, Robinson C, Taylor BK, Murthy SN, Champion HC, Hellstrom WJ, Kadowitz PJ. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. *Am J Physiol Heart Circ Physiol* 2007; **292**: H1278-H1290
- 30 **Song YS**, Lee HJ, Park IH, Kim WK, Ku JH, Kim SU. Potential differentiation of human mesenchymal stem cell transplanted in rat corpus cavernosum toward endothelial or smooth muscle cells. *Int J Impot Res* 2007; **19**: 378-385
- 31 **Fall PA**, Izikki M, Tu L, Swieb S, Giuliano F, Bernabe J, Souktani R, Abbou C, Adnot S, Eddahibi S, Yiu R. Apoptosis and effects of intracavernous bone marrow cell injection in a rat model of postprostatectomy erectile dysfunction. *Eur Urol* 2009; **56**: 716-725
- 32 **Nolazco G**, Kovanecz I, Vernet D, Gelfand RA, Tsao J, Ferrini MG, Magee T, Rajfer J, Gonzalez-Cadavid NF. Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. *BJU Int* 2008; **101**: 1156-1164
- 33 **Ning H**, Liu G, Lin G, Yang R, Lue TF, Lin CS. Fibroblast growth factor 2 promotes endothelial differentiation of adipose tissue-derived stem cells. *J Sex Med* 2009; **6**: 967-979

S- Editor Li LF L- Editor Lutze M E- Editor Yang C

The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents

Umberto Galderisi, Antonio Giordano, Marco G Paggi

Umberto Galderisi, Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, PA 19122, United States

Umberto Galderisi, Department of Experimental Medicine, Biotechnology and Molecular Biology Section, Second University of Naples, Naples 80138, Italy; Human Health Foundation, Terni 05100, Italy

Antonio Giordano, Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, PA 19122, United States; Human Health Foundation, Terni 05100, Italy

Marco G Paggi, National Cancer Institute "Regina Elena", Rome 00144, Italy

Author contributions: Galderisi U, Giordano A and Paggi MG performed analysis interpretation of data, drafted the article and finally approved the version to be published.

Supported by Grants from Associazione Italiana Ricerca sul Cancro (AIRC) to Paggi MG; Ministero della Salute grants to Paggi MG; and from Sbarro Health Research Organization funds to Galderisi U and Giordano A

Correspondence to: Umberto Galderisi, PhD, Department of Experimental Medicine, Biotechnology and Molecular Biology Section, Second University of Naples, Via Costantinopoli 16, Napoli 80138, Italy. umberto.galderisi@unina2.it

Telephone: +39-81-5667585 Fax: +39-81-5667547

Received: December 1, 2009 Revised: January 12, 2010

Accepted: January 19, 2010

Published online: February 26, 2010

Recently, MSC sustainment of cancer cell growth is a hot research topic. Indeed, these cells are known to sustain tumor angiogenesis and metastasis formation, to create a microenvironment favorable for cancer cell growth and to down-modulate the immune system capabilities in the host organism. On the other hand, since scientists became able to take advantage of their extremely selective capability to target cancer cells, MSCs are now also thought of in a different light. Indeed, MSCs are now considered a promising vehicle for local expression or delivery of even particularly toxic anticancer agents, ranging from Herpes Simplex Virus to locally-acting antineoplastic drugs. On this basis, investigation is now focused on how to impair the pro-neoplastic features of MSCs on one hand whilst taking advantage of their specific tropism toward cancer cells, on the other. As with the two faces of Janus, this review will concisely explore the research activity in these two apparently conflicting fields.

© 2010 Baishideng. All rights reserved.

Key words: Mesenchymal stem cells; Cancer; Cell therapy; Angiogenesis; Niche; Immunomodulation

Peer reviewer: Chie-Pein Chen, MD, PhD, Division of High Risk Pregnancy, Mackay Memorial Hospital, 92 Sec 2, Zhong-Shan North Road, Taipei 104, Taiwan, China

Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. *World J Stem Cells* 2010; 2(1): 5-12 Available from: URL: <http://www.wjgnet.com/1948-0210/full/v2/i1/5.htm> DOI: <http://dx.doi.org/10.4252/wjsc.v2.i1.5>

Abstract

In cancer biology, mesenchymal stem cells (MSCs) display aspects that can appear contradictory. On one hand, these cells possess several features which give them the ability to specifically target and then sustain cancer cells in their ability to survive the multifaceted host response against cancer. On the other hand, due to this excellent aptitude to home-in on tumor tissues, regardless their location in the host's body, MSCs are considered to be extremely selective vehicles to reach cancer cells specifically.

INTRODUCTION

The microenvironment of mammalian bone marrow is composed of several different elements that support

hematopoiesis and bone homeostasis^[1,2]. It includes a heterogeneous population of cells: macrophages, fibroblasts, adipocytes, osteoprogenitors, endothelial cells and reticular cells. Among these, there are also non-hematopoietic stem cells that possess a multilineage potential^[3,4]. These stem cells are commonly described as marrow stromal stem cells or mesenchymal stem cells (MSCs). Mesenchymal cells are primordial cells of mesodermal origin, able to give rise to skeletal muscle cells, vascular and urogenital systems and to connective tissues throughout the body (Figure 1)^[5-7]. For this reason, the word “mesenchymal” should not be used to refer to stem cells that are also able to produce blood cells and which derive from a distinct stem cell population present in the bone marrow: the hemopoietic stem cells (HSCs)^[5-7].

MSCs can be hence considered non-hematopoietic, multi-potent stem-like cells that are capable of differentiating into both mesenchymal and non-mesenchymal lineages. In fact, in addition to bone, cartilage, fat and myoblasts, MSCs have been demonstrated to be capable of differentiating into neurons and astrocytes, *in vitro* and *in vivo*^[7-10].

MSCs are of interest because they can easily be isolated from a small aspirate of bone marrow and expanded through as many as 50 population doublings in about 10 wk. As such, these cells are currently being tested for their potential use in cell and gene therapy for a number of human diseases. Nevertheless, there are still some open questions about the origin, multipotentiality and anatomical localization of MSCs. As far as this latter point is concerned, it has been shown that MSCs can be isolated from different tissues other than bone marrow, although this remains the primary source for obtaining these stem cells. Indeed, MSCs have been successfully isolated from adipose tissue, liver, tendons, synovial membrane, amniotic fluid, placenta, umbilical cord and teeth^[5-8].

Another hot issue is the lack of an unambiguous single marker to clearly define MSCs. In fact, at the present, MSCs are identified through a combination of physical, phenotypic and functional properties. The classical methodology utilized to identify MSCs is the colony forming unit assay, which recognizes adherent spindle-shaped cells that proliferate to form colonies and that can be induced to differentiate into adipocytes, osteocytes and chondrocytes^[5-8].

Further obstacles in defining MSCs arise from the fact that different laboratories have employed different sources, extraction and cultivation methods. These variables are clearly responsible for the phenotype and function of the resulting cell populations. Whether these conditions selectively promote the expansion of different populations of MSCs or cause similar cell populations to acquire different phenotypes is still not clear^[7]. For this reason, it is not possible to define the relationships between MSCs and other stem cell populations which are similar to MSCs but defined with a different nomenclature, such as bone marrow stromal stem cells, stromal precursor cells, recycling stem cells, marrow isolated adult multilineage inducible stem

cells (MIAMI cells) and multi-potent adult progenitor cells (MAPC) (Figure 1)^[7,11,12]. MIAMI and MAPC stem cells display a higher proliferative and differentiative potential compared to classical MSCs. These cells have been suggested to represent a more primitive subset of stem cells, the possible common precursor of MSCs and HSCs^[7,11,12]. If this is the case, then the relationship between these cell populations and the hemangioblasts, considered the mesodermal precursors of hematopoietic and endothelial cell lineages, has to be determined^[6,13].

HOMING OF MSCS IN TUMOR TISSUES

Several researches have demonstrated that MSCs can efficiently home to injured tissues and actively participate to tissue repair. MSCs can repair injured tissues by secreting cytokines and growth factors that can restore tissue homeostasis, by reducing local inflammation and by differentiating in one or more of the cell types resident in the injured tissues^[3,10,14].

Tumor microenvironment may be considered similar to that of an injured tissue. For this reason, tumor growth often appears associated with several types of stromal cells in a manner that overlaps wound healing and tissue repair processes. In tumors, bone marrow-derived MSCs, hematopoietic stem cells and endothelial progenitors cells are recruited to establish a supportive stroma, a phenomenon elicited by the release of endocrine and paracrine signals, as observed in injured tissues. Signaling molecules, such as CXCR4, CXCR12 and CCL12 are involved in tumor homing of MSCs^[15]. The exact homing mechanism has not been fully elucidated, since several studies have addressed this issue by studying migratory properties of MSCs derived from *in vitro* cultures. During *in vitro* growth, MSCs often lose the expression of chemokine receptors and thus responsiveness to chemokines^[16], a phenomenon that could bias data interpretation on the homing process. In fact, MSCs harvested after a few days of *in vitro* growth may express a different pattern of chemokine receptors compared with cells that have been cultivated for a longer time.

On the other hand, a complete analysis on the mobilization to tumor regions of endogenous bone marrow resident MSCs is still underway. There are, however, several pieces of evidence showing a major contribution of MSCs to the formation of tumor stroma. For example, Haniffa and co-workers suggest that mesenchymal fibroblasts within solid tumors (also called carcinoma-associated fibroblasts) originate from bone marrow MSCs^[17]. Moreover, other investigators show that, in pancreatic tumors, about 25% of myofibroblasts derive from bone marrow cells^[18,19].

CONTRIBUTION OF MSCS TO TUMOR GROWTH

MSCs that reach tumor stroma may contribute to tumor growth in several ways: (1) by promoting angiogenesis; (2)




Figure 1 Diagram of mesenchymal stem cell hierarchy. At top of diagram are indicated the MAPCs that possess a higher proliferative and differentiative potential compared to classical MSCs. These may represent a more primitive subset of stem cells that could be the common precursor of MSCs, HSCs and EPCs. In the diagram are indicated the mesenchymal and non-mesenchymal cell types that originate from these different classes of stem cells. The dashed lines indicate putative differentiation pathways. MSCs: Mesenchymal stem cells; MAPCs: Multi-potent adult progenitor cells; HSCs: Hematopoietic stem cells; EPCs: Endothelial progenitor cells.

by creating a niche to support cancer stem cells survival; (3) by modulating the organism's immune response against cancer cells; and (4) by promoting formation of metastasis (Figure 2).

Promotion of angiogenesis

MSCs can contribute to tumor vessel formation either by producing growth factors acting on tumor cells, endothelial cells and smooth muscle cells or by producing angiogenic growth factors (VEGF, PDGF, bFGF, SDF-1). MSC-derived angiogenic factors can promote proliferation, survival and migration of endothelial cells, thus contributing to vessel formation. Similarly, MSCs appear able to promote smooth muscle cell proliferation and migration^[20-22]. MSCs can also contribute to vessel formation by differentiating into endothelial cells, smooth muscle cells and pericytes. The latter are elongated cells of mesodermal origin that partially surround the endothelial cells of small vessels and are involved in the maintenance of microvascular homeostasis. *In vitro*, MSCs can differentiate into endothelial cells following treatment with VEGF and are also capable of forming vessel-like structures when cultured on tri-dimensional Matrigel^[23-26]. Annabi and co-workers show that subcutaneous co-injection of MSCs and malignant glioma cells in nude mice results in formation of highly vascularized tumors. In these tumors, MSCs differentiate into endothelial-like cells and localize at the lumen of vascular structures^[27]. These investigators suggest that MSCs could be recruited at the sites of active tumor neovascularization through paracrine regulation of their angiogenic properties. The ability of MSCs to differentiate into smooth muscle cells has been demonstrated at least in ischemia models. In a dog model of cardiac ischemia, intramyocardial injection of MSCs




Figure 2 MSCs may contribute to tumor growth in several ways: Promoting angiogenesis; Creating a niche to support cancer stem cells survival; Modulating the organism's immune response against cancer cells; Promoting formation of metastasis.

results in differentiation into smooth muscle cells and endothelial cells with increased vascularity and improved cardiac function^[28].

Niche for cancer cell survival

Osteoblasts derived from MSCs are key components of the hematopoietic stem cell niche, a specialized microenvironment that provides cytokine and cell contact signals to regulate stem cell physiology^[2,29]. On this premise, a tantalizing hypothesis arises from studies of Dazzi and co-workers^[30] that show that MSCs are able to inhibit proliferation of hematopoietic and non-hematopoietic tumors *in vitro*. This phenomenon is associated with a reduction of apoptosis even in stress conditions, such as low concentration of survival factors. Nevertheless, when tumor cells and MSCs are co-injected into immunodeficient mice, cancer cells grew much faster as compared to the group receiving only tumor cells. To explain this discrepancy between *in vitro* and *in vivo* data, the authors suggest that MSCs have the ability to form a cancer stem cell niche, in which tumor cells can preserve the potential to proliferate, are protected from apoptosis and can thus sustain the malignant process^[30].

Drug resistance in acute myelogenous leukemia cells is induced by the attachment of very late antigen (VLA)-4 of leukemic cells to fibronectin on bone-marrow stromal cells. VLA-4-positive cells acquire resistance to loss of anchorage or drug-induced apoptosis through the PI-3K/AKT/Bcl-2 signaling pathway, which is activated by the interaction of VLA-4 and fibronectin^[31].

Immune response modulation

Immunosuppressive activity of MSCs can promote tumor growth by impairing rejection of cancer cell by the immune system. Jorgensen's group investigated whether *in vivo* injection of MSCs could display side effects related to systemic immunosuppression, thus favoring tumor growth^[32]. Using the murine B16 melanoma model, they

showed that subcutaneous injection of melanoma cells leads to tumor growth in allogeneic recipients only when MSCs are co-injected^[32].

Promotion of metastasis formation

MSCs may also promote the metastatic process. In fact, several reports point out that MSCs are recruited in large number to the stroma of developing tumors^[33]. Karnoub and co-workers characterized the role of MSCs in tumorigenesis, thus demonstrating that these stem cells may promote breast cancer metastasis^[34]. They investigated, in detail, the functional consequences of the interaction between MSCs and mammary carcinoma cells in a mouse xenograft model. Human breast cancer cells were mixed with MSCs and injected subcutaneously into immunocompromised mice. MSCs appear to accelerate tumor growth in mice along with a significantly increased presence of micro- and macroscopic lung metastases. Explants of primary tumors and lung metastases were then expanded *in vitro* and re-injected subcutaneously into host mice, in order to evaluate their respective metastatic power. Under these conditions, lung metastasis-derived cells show the same metastatic potential of the primitive tumor-derived cells. The authors thus suggest that the MSC-induced metastatic power reflects a reversibly induced trait of breast cancer cells, and that the ability of these cells to metastasize is a consequence of their “education” by MSCs, rather than a clonal selection of rare variants with higher metastatic power^[34]. These findings indicate that MSCs supply local-acting paracrine signals that induce breast cancer cells to metastasize. On the other hand, breast cancer cells stimulate the secretion of the chemokine CCL5 from MSCs, which then acts in a paracrine way on cancer cells to enhance their motility, invasion and metastasis^[34].

In the investigations described above, MSCs migrating from bone marrow to primary tumors can promote the acquisition of metastatic properties to cancer cells while, complementarily, MSCs residing in bone marrow may render this organ a privileged site for metastases. To elucidate this process, the molecular mechanisms of MSC interaction with breast cancer cells have been addressed, and the role of stromal cell-derived factor 1 α (SDF-1 α) has received great attention. SDF-1 α belongs to the chemokine family and is constitutively produced in bone marrow stroma cells (including MSCs). The SDF-1 protein has two isoforms (α and β) which both interact with CXCR4 receptors. Breast cancer cells expressing CXCR4 may migrate toward organs with high levels of SDF-1 α , such as bone marrow^[35]. Bone metastases have been reported also in the absence of a clinically evident primary breast cancer, thus suggesting a migration of cancer cells during the early phases of the disease. These cancer cells can be supported by the bone marrow microenvironment and are likely to survive chemotherapy.

MSCs possess the potential to give rise to a wide variety of differentiated cell types, and the stem cell hypothesis of cancer onset postulates that they may also be the

origin of an interesting range of cancers, such as osteosarcoma, chondrosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, *etc*^[36]. Indeed, MSCs can undergo spontaneous transformation following *in vitro* culture. Rubio and co-workers show that, although MSCs can be managed safely during the standard *in vitro* expansion period (6-8 wk), human MSCs can be subjected to spontaneous transformation following long-term *in vitro* culture (4-5 mo)^[37]. Another study demonstrates that MSCs transduced with the telomerase (*TERT*) gene undergo neoplastic transformation. One of the *TERT*-transduced clones at population doubling 256 showed loss of contact inhibition, anchorage independence and 100% tumorigenicity when injected into immuno-deficient mice (tumor take in 10 out of 10 animals)^[38]. Another interesting study analyzes the relationship between MSC transformation and cancer during aging of the individual^[39]. Peripheral and bone marrow-derived stem cells are long-lived and are candidate cells for the “cancer-initiating cell”. Based on the facts that MSCs can undergo neoplastic transformation and that tumors in aged C57BL/6 mice are frequently fibrosarcomas, Li and co-workers used a genetically tagged bone marrow (BM) transplant model to show that aged mice develop MSC-derived fibrosarcomas^[39]. They also show that, MSCs transform spontaneously in culture with aging and that, when placed into a mouse model, they replicate the naturally occurring fibrosarcomas of the aged mice, showing similarly altered gene expression changes and, specifically, p53 mutation. Of great interest, spontaneously transformed MSCs contribute directly to the tumor formation, tumor vasculature, and tumor adipose tissue, recruit additional host BM-derived cells (BMDC) to the area, and fuse with the host BMDC^[39].

MSCs AS VEHICLE FOR ANTICANCER DRUGS

MSCs are attractive as a vehicle for the expression of therapeutic proteins by gene transfer, since they are easy in harvesting, isolation and expansion, transducibility with viral vectors, systemic or local delivery and are refractory to host immune response. As MSCs have the capacity to home to the tumor microenvironment, they may thus be promising tools for the selective delivery of antineoplastic drugs to tumors (Figure 3).

A pioneering study has been carried out by Studeny and collaborators^[40]. They demonstrate that, for the purpose of anticancer therapy, MSCs can produce biological agents locally at tumor sites. In detail, they show that MSCs with forced expression of IFN- β inhibit the growth of malignant cells *in vivo*. Importantly, this effect requires the physical integration of MSCs into the tumors and cannot be achieved by systemically delivered IFN- β or by IFN- β produced by MSCs at sites distant from the tumor^[40]. In detail, these investigators transduced MSCs with an adenoviral expression vector carrying the human IFN- β gene. Co-culture of IFN- β -expressing MSCs (MSC-




Figure 3 Mesenchymal stem cells as vehicle for anticancer drug. In the Figure are indicated the vectors used to engineer MSCs and the “therapeutical genes”. Target cancer cells are in parenthesis. MSCs: Mesenchymal stem cells; IL12: Interleukin-12; IFN- γ : Interferon-gamma; TRAIL: Tumor necrosis (TNF)-related apoptosis-inducing ligand.

IFN- β), cells with A375SM melanoma cells or MDA 231 breast carcinoma cells inhibited tumor cell growth as compared with the growth of tumor cells cultured alone. Intravenous injection of MSC-IFN- β cells into mice with established MDA 231 or A375SM pulmonary metastases led to incorporation of MSCs in the tumor architecture and to prolonged survival, when compared with untreated control mice^[40,41]. This research is the proof of principle that MSCs may serve as a valid platform for selective delivery of biological agents in tumors.

Another interesting application of MSCs has been demonstrated for the treatment of malignant gliomas. Patients with malignant glioma often have a poor prognosis, partly related to the inability to deliver efficiently therapeutic agents to the tumor, due to the presence of the blood brain barrier. Nakamizo *et al.*^[42] hypothesized that MSCs may have a strong tropism for brain tumors and thus could be used as delivery vehicles for malignant glioma therapy. To test this, they isolated MSCs from bone marrow of healthy volunteers. These cells were fluorescently labeled and then injected into the carotid artery of mice bearing intracranial xenografts of a human malignant glioma. Interestingly, homing of these labeled MSCs occurred efficiently within the brain tumors, regardless of whether the cells were injected into the ipsilateral or contralateral carotid artery. In contrast, intracarotid injections of fibroblasts or U87 malignant glioma cells resulted in a widespread distribution of delivered cells without tumor specificity. In order to evaluate the potential of MSCs to deliver a therapeutic agent, these investigators engineered stem cells to release IFN- β . *In vivo* experiments showed that treatment of intracranial U87 xenografts with MSC-IFN- β significantly increases animal survival when compared with controls.

Another approach to the treatment of tumors was to use MSCs as a vehicle to deliver oncolytic viruses to tumor sites. Natural and genetically modified oncolytic viruses,

such as replicative adenoviruses, have been systematically tested as anticancer therapeutics. Unfortunately, clinical trials have shown limited antitumor efficacy, partly due to insufficient viral delivery to tumor sites. Komarova and colleagues infected MSCs with an adenovirus, genetically modified for coxsackie and adenovirus receptor-independent infection (Ad5/3), which replicates in the carrier cells^[43]. MSCs loaded with Ad5/3 cause total cell killing when co-cultured with a cancer cell line. In an animal model of ovarian cancer, MSC-based delivery of Ad5/3 increases the survival of tumor-bearing mice compared with direct viral injection. Tumor imaging analyses confirmed a decrease in tumor burden in animals treated with oncolytic virus delivered by MSC carriers compared with the direct injection of the adenovirus^[43].

A similar approach was used by Curiel and collaborators for the treatment of breast cancer^[44]. MSCs were transduced with conditionally replicating adenoviruses (CRADs) and a SCID mouse xenograft model was used to examine the effects of systemically injected CRAD-loaded MSCs or CRAD alone on the growth of pulmonary metastases of breast cancer *in vivo*. The intravenous injection of CRAD-loaded MSCs homed to the tumor site and led to extended mouse survival compared to mice treated with CRAD alone^[44].

Retroviral vectors have also been used to obtain MSCs expressing therapeutic molecules. Pavlovic’s group evaluated the anti-tumor activity of human MSCs, stably transduced with a retroviral vector expressing the cytokine Interleukin-12 (IL-12) in a mouse melanoma model. MSCs expressing IL-12 significantly reduced the formation of lung metastases of B16F10 melanoma cells^[45]. The therapeutic effectiveness of IL-12-expressing MSCs is in part mediated by CD8(+) T cells, while natural killer cells and CD4(+) T cells appear to play a minor role^[45].

Suicide gene therapy has been tested for the treatment of invasive tumors. In this context, treatments have been developed using retroviral vectors expressing the thymidine kinase of Herpes Simplex Virus combined with the prodrug ganciclovir. For a safe and effective procedure, it is essential that the vector has a tumor tracking property to selectively and effectively attack invasive or metastatic lesions with minimal adverse effects. Uchibori and co-workers developed MSCs that locally express the HSV-tk-expressing retroviral vectors (VPMSCs)^[46]. Systemic delivery of modified MSCs results in enhanced transgene expression in the 9L malignant glioma tumors in mice. VPMSC administration was accompanied by a significant suppression of tumor growth^[46].

Other authors have introduced suicide genes into MSCs to produce a tumor-specific prodrug-converting cellular vehicle for targeted chemotherapy. Kucerova and collaborators used retroviral transduction to introduce the fusion gene cytosine deaminase/uracil phosphoribosyltransferase into adipose derived MSCs^[47]. Cytosine deaminase (CD) converts cytosine to uracil and ammonia, providing an important mechanism for pyrimidine salvage in

microbes. Because this activity is not found in mammalian cells, CD is being explored for use in suicide gene therapy, due to its ability to also convert the antifungal agent 5-fluorocytosine (5FC) to the potent antimetabolite drug, 5-fluorouracil (5FU). In the cell, 5FU is metabolized by endogenous enzymes to 5FdUMP, an irreversible inhibitor of thymidylate synthetase, thereby restricting the production of dTMP and downstream phosphorylated products. Depletion of dTTP pools results in inhibition of DNA synthesis and, consequently, to apoptosis^[48].

Several reports demonstrate that lentiviral transduction is more efficient than onco-retroviral transduction and improves engraftment of MSCs without affecting their stem cell properties. Sasportas and co-workers showed that human MSCs are efficiently transduced with lentiviral vectors and migrate efficiently to tumor sites in a mouse model of human glioblastoma^[49]. These authors then evaluated the effectiveness of MSCs transduced with lentiviruses expressing the TNF-related apoptosis inducing ligand (TRAIL). The ability of TRAIL to selectively target tumor cells, while remaining harmless to most normal cells, makes this an attractive candidate for an apoptotic therapy in tumor treatment. TRAIL signals *via* two pro-apoptotic death receptors (DR4 and DR5), inducing a caspase-8-dependent apoptotic cascade in tumor cells. The Sasportas group developed MSCs producing a secretable form of TRAIL. These cells were able to induce caspase-3-mediated apoptosis in GBM8 cells, a CD133-positive primary brain tumor cell line *in vitro*, and, when implanted into established GBM8 tumors, resulting in a significant increase in survival of mice bearing malignant gliomas^[49].

In another study, researchers produced MSCs expressing TNF α -Tumstatin gene following lentivirus gene transduction. The effects of this approach have been evaluated on human prostate cancer cells by co-culturing them with engineered MSCs *in vitro*. The antitumor effects of these cells were then determined in PC3 prostate cancer cells *in vivo*. The results showed that engineered MSCs both inhibited proliferation and induced apoptosis in prostate cancer cells and xenograft tumors^[50].

CONCLUSION

At this point, it appears clear why MSCs are acquiring such relevance in cancer cell biology as well as in antineoplastic pharmacology. There are, however, some concerns, mainly in the therapeutic approach. The key questions raised are: (1) How specific would the MSC targeting capability towards cancer cells be? In other words, are we sure that the use of such toxic substances by these “armed” MSCs is safe enough and delivered only to tumor cells? (2) How dangerous could such a targeted cancer cure using MSCs be for the patient, if we consider their elevated susceptibility to undergo spontaneous cell transformation?

Stemness is a characteristic which appears often associated with cancer onset and progression. It is well known that many recent findings support the notion that cells

whose properties reproduce those of stem cells appear essential for both development and continuation of a substantial number of human cancers. Eradication of the stem cell compartment of a tumor is thus considered a prerequisite for a complete cancer remission or even total cure of the disease. For this reason, it should be unquestionable that the cancer propensity of MSC is really under control when these cells are used in cancer therapy. Once again, we realize that we are dealing with a double-edged sword and that only a strong further commitment by the scientific community is the real weapon against cancer.

ACKNOWLEDGMENTS

We thank Dr. Nicola Alessio for his technical assistance in figure set-up.

REFERENCES

- 1 Müller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem cell universe. *Stem Cells* 1995; **13**: 477-486
- 2 Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. Identification of the haematopoietic stem cell niche and control of the niche size. *Nature* 2003; **425**: 836-841
- 3 Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. *Stem Cells* 2001; **19**: 180-192
- 4 Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. *Exp Hematol* 2000; **28**: 875-884
- 5 Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science* 1997; **276**: 71-74
- 6 Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. *Ageing Res Rev* 2006; **5**: 91-116
- 7 Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation, *in vitro* expansion and characterization. *Handb Exp Pharmacol* 2006; **249**: 249-282
- 8 Bianco P, Gehron Robey P. Marrow stromal stem cells. *J Clin Invest* 2000; **105**: 1663-1668
- 9 Jori FP, Melone MA, Napolitano MA, Cipollaro M, Cascino A, Giordano A, Galderisi U. RB and RB2/p130 genes demonstrate both specific and overlapping functions during the early steps of *in vitro* neural differentiation of marrow stromal stem cells. *Cell Death Differ* 2005; **12**: 65-77
- 10 Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999; **284**: 143-147
- 11 D'Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. *J Cell Sci* 2004; **117**: 2971-2981
- 12 Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM. Purification and *ex vivo* expansion of postnatal human marrow mesodermal progenitor cells. *Blood* 2001; **98**: 2615-2625
- 13 Park C, Ma YD, Choi K. Evidence for the hemangioblast. *Exp Hematol* 2005; **33**: 965-970
- 14 Spees JL, Olson SD, Ylostalo J, Lynch PJ, Smith J, Perry A, Peister A, Wang MY, Prockop DJ. Differentiation, cell fusion, and nuclear fusion during *ex vivo* repair of epithelium by human adult stem cells from bone marrow stroma. *Proc Natl Acad Sci USA* 2003; **100**: 2397-2402
- 15 Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ,

- Hennessy E, Murphy JM, Barry FP, O'Brien T, Kerin MJ. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. *Clin Cancer Res* 2007; **13**: 5020-5027
- 16 **Honczarek M**, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. *Stem Cells* 2006; **24**: 1030-1041
- 17 **Haniffa MA**, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, Hilkens CM, Collin MP. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. *J Immunol* 2007; **179**: 1595-1604
- 18 **Direkze NC**, Hodivala-Dilke K, Jeffery R, Hunt T, Poulosom R, Oukrif D, Alison MR, Wright NA. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. *Cancer Res* 2004; **64**: 8492-8495
- 19 **Sangai T**, Ishii G, Kodama K, Miyamoto S, Aoyagi Y, Ito T, Magae J, Sasaki H, Nagashima T, Miyazaki M, Ochiai A. Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma. *Int J Cancer* 2005; **115**: 885-892
- 20 **Gruber R**, Kandler B, Holzmann P, Vögele-Kadletz M, Losert U, Fischer MB, Watzek G. Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. *Tissue Eng* 2005; **11**: 896-903
- 21 **Kinnaird T**, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circ Res* 2004; **94**: 678-685
- 22 **Potapova IA**, Gaudette GR, Brink PR, Robinson RB, Rosen MR, Cohen IS, Doronin SV. Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. *Stem Cells* 2007; **25**: 1761-1768
- 23 **Al-Khalidi A**, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K, Galipeau J. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. *Gene Ther* 2003; **10**: 621-629
- 24 **Liu JW**, Dunoyer-Geindre S, Serre-Beinier V, Mai G, Lambert JF, Fish RJ, Pernod G, Buehler L, Bounameaux H, Kruihof EK. Characterization of endothelial-like cells derived from human mesenchymal stem cells. *J Thromb Haemost* 2007; **5**: 826-834
- 25 **Oswald J**, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. *Stem Cells* 2004; **22**: 377-384
- 26 **Wu X**, Huang L, Zhou Q, Song Y, Li A, Jin J, Cui B. Mesenchymal stem cells participating in ex vivo endothelium repair and its effect on vascular smooth muscle cells growth. *Int J Cardiol* 2005; **105**: 274-282
- 27 **Annabi B**, Naud E, Lee YT, Eliopoulos N, Galipeau J. Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. *J Cell Biochem* 2004; **91**: 1146-1158
- 28 **Silva GV**, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, Coulter SC, Lin J, Ober J, Vaughn WK, Branco RV, Oliveira EM, He R, Geng YJ, Willerson JT, Perin EC. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. *Circulation* 2005; **111**: 150-156
- 29 **Calvi LM**, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT. Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature* 2003; **425**: 841-846
- 30 **Ramasamy R**, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. *Leukemia* 2007; **21**: 304-310
- 31 **Matsunaga T**, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, Kato J, Hirayama Y, Sakamaki S, Kohda K, Miyake K, Niitsu Y. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. *Nat Med* 2003; **9**: 1158-1165
- 32 **Djouad F**, Plerce P, Bony C, Tropel P, Apparailly F, Sany J, Noël D, Jørgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. *Blood* 2003; **102**: 3837-3844
- 33 **Hall B**, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. *Handb Exp Pharmacol* 2007; **263**-283
- 34 **Karnoub AE**, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. *Nature* 2007; **449**: 557-563
- 35 **Moharita AL**, Taborga M, Corcoran KE, Bryan M, Patel PS, Rameshwar P. SDF-1alpha regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. *Blood* 2006; **108**: 3245-3252
- 36 **Keith WN**. From stem cells to cancer: balancing immortality and neoplasia. *Oncogene* 2004; **23**: 5092-5094
- 37 **Rubio D**, Garcia-Castro J, Martín MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A. Spontaneous human adult stem cell transformation. *Cancer Res* 2005; **65**: 3035-3039
- 38 **Serakinci N**, Guldberg P, Burns JS, Abdallah B, Schrødder H, Jensen T, Kassem M. Adult human mesenchymal stem cell as a target for neoplastic transformation. *Oncogene* 2004; **23**: 5095-5098
- 39 **Li H**, Fan X, Kovi RC, Jo Y, Moquin B, Konz R, Stoicov C, Kurt-Jones E, Grossman SR, Lyle S, Rogers AB, Montrose M, Houghton J. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. *Cancer Res* 2007; **67**: 10889-10898
- 40 **Studeny M**, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. *Cancer Res* 2002; **62**: 3603-3608
- 41 **Studeny M**, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. *J Natl Cancer Inst* 2004; **96**: 1593-1603
- 42 **Nakamizo A**, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. *Cancer Res* 2005; **65**: 3307-3318
- 43 **Komarova S**, Kawakami Y, Stoff-Khalili MA, Curriel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. *Mol Cancer Ther* 2006; **5**: 755-766
- 44 **Stoff-Khalili MA**, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, Rocconi RP, Numnum TM, Everts M, Chow LT, Douglas JT, Siegal GP, Zhu ZB, Bender HG, Dall P, Stoff A, Pereboeva L, Curriel DT. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. *Breast Cancer Res Treat* 2007; **105**: 157-167
- 45 **Elzaouk L**, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma

- model. *Exp Dermatol* 2006; **15**: 865-874
- 46 **Uchibori R**, Okada T, Ito T, Urabe M, Mizukami H, Kume A, Ozawa K. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. *J Gene Med* 2009; **11**: 373-381
- 47 **Kucerova L**, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. *Cancer Res* 2007; **67**: 6304-6313
- 48 **Fuchita M**, Ardiani A, Zhao L, Serve K, Stoddard BL, Black ME. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. *Cancer Res* 2009; **69**: 4791-4799
- 49 **Sasportas LS**, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. *Proc Natl Acad Sci USA* 2009; **106**: 4822-4827
- 50 **Zhang X**, Xu W, Qian H, Zhu W, Zhang R. Mesenchymal stem cells modified to express lentivirus-TNFalpha-Tumstatin inhibit the growth of prostate cancer. *J Cell Mol Med* 2009; [Epub ahead of print]

S- Editor Li LF L- Editor Hughes D E- Editor Yang C

Acknowledgments to reviewers of *World Journal of Stem Cells*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Stem Cells*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

Philippe Bourin, MD, PhD, Laboratoire de thérapie cellulaire, EFS-PM, 75 rue de Lisieux, Toulouse 31300, France

Chie-Pein Chen, MD, PhD, Division of High Risk Pregnancy, Mackay Memorial Hospital, 92 Sec. 2, Zhong-Shan North Road, Taipei 104, Taiwan, China

Todd Evans, PhD, Professor, Department of Surgery, Weill Cornell Medical College of Cornell University, 1300 York Ave. LC-709, New York, NY 10065, United States

Ursula Margarethe Gehling, MD, Paul-Ehrlich-Institute, Paul-Ehrlich-Strasse 51 – 59, 63225 Langen, Germany

Nadya L Lumelsky, PhD, National Institute of Dental and Craniofacial Research, National Institutes of Health, 6701 Democracy Blvd. Room 618, Bethesda, MD 20892-4878, United States

Hong-Bo R Luo, Assistant Professor, Department of Pathology and Lab Medicine, Harvard Medical School and Children's Hospital Boston, 10214 Karp Research Building, 1 Blackfan Circle, Boston, MA 02115, United States

Murielle Mimeault, PhD, Department of Biochemistry and Molecular Biology, College of Medicine, Eppley Cancer Institute, 7052 DRC, University of Nebraska Medical Center, 985870 Nebraska Medical Center, Omaha, NE 68198-5870, United States

Takashi Tada, Professor, Stem Cell Engineering, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

Xavier Thomas, MD, PhD, Department of Hematology, Edouard Herriot Hospital, Place d' Arsonval, 69437, cedex 03, Lyon, France

Meetings



Events Calendar 2010

February 15-16, 2010
 Stem Cells 2010
 Crowne Plaza Hotel, St James, London,
 United Kingdom

May 11-13, 2010
 World Stem Cells and Regenerative
 Medicine Congress
 London, United Kingdom
<http://www.terrapinn.com/2010/stemcells/index.stm>

May 12-15, 2010
 Stem Cells, Tissue Homeostasis and
 Cancer
 EMBL Heidelberg, Germany
http://www.embl.de/training/courses_conferences/conference/2010/STM10-01/

August 22-27, 2010
 The 2010 Gordon Conference on Cell
 Death
 Salve Regina University, Newport,
 RI, United States

October 4-6, 2010
 World Stem Cell Summit 2010
 Detroit Marriott Renaissance Center,
 Detroit, Michigan, United States
<http://www.worldstemcellsummit.com/>




June 16-19, 2010
 ISSCR 8th Annual Meeting
 Moscone West, San Francisco, CA
 United States
<http://www.isscr.org/meetings/index.cfm>



June 27-July 2, 2010
 The 9th Gordon Conference on Cell
 Biology of the Neuron
 Waterville Valley Resort, NH,
 United Kingdom

July 11-14, 2010
 3rd International Congress on Stem
 Cells and Tissue Formation
 Dresden, Germany
<http://www.stemcellcongress-dresden.org/>



Instructions to authors

GENERAL INFORMATION

World Journal of Stem Cells (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a bimonthly, open-access (OA), peer-reviewed journal supported by an editorial board of 284 experts in stem cell from 28 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJSC* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJSC* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJSC* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits of editorial board

members, authors and readers, and yielding the greatest social and economic benefits.

The major task of *WJSC* is to report rapidly original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including: Embryonic, neural, hematopoietic, mesenchymal, tissue-specific, and cancer stem cells; the stem cell niche; stem cell genomics and proteomics; and stem cell techniques and their application in clinical trials. Papers published in *WJSC* will cover the biology, culture, differentiation and application of stem cells from all stages of their development, from germ cell to embryo and adult.

The columns in the issues of *WJSC* will include: (1) Editorial: To introduce and comment on the substantial advance and its importance in the fast-developing areas; (2) Frontier: To review the most representative achievements and comment on the current research status in the important fields, and propose directions for the future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide Guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To systematically review the most representative progress and unsolved problems in the major scientific disciplines, comment on the current research status, and make suggestions on the future work; (8) Original Article: To originally report the innovative and valuable findings in stem cells; (9) Brief Article: To briefly report the novel and innovative findings in stem cells; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJSC*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of stem cells; and (13) Guidelines: To introduce Consensuses and Guidelines reached by international and national academic authorities worldwide on basic research and clinical practice in stem cells.

CSSN
ISSN 1948-0210 (online)

Published by
Beijing Baishideng BioMed Scientific Co., Ltd.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Beijing Baishideng BioMed Scientific Co., Ltd, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals

Instructions to authors

of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the International Committee of Medical Journal Editors to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/1948-0210office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (<http://www.wjgnet.com/1948-0210/index.htm>) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjsc@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of

supportive foundations should be provided, e.g., Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g., Telephone: +86-10-59080039 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJSC*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$; CONCLUSION (no more than 26 words). Available from: <http://www.wjgnet.com/wjg/help/8.doc>

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles, rapid communication and case reports, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: <http://www.wjgnet.com/wjg/help/instructions.jsp>.

Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are

applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first

and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer

Instructions to authors

disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/EID/eid.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as ν (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 $24.5 \mu\text{g/L}$; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: <http://www.wjgnet.com/wjg/help/15.doc>.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJSC*. The revised version including manuscript and high-resolution image figures (if any) should be copied on a floppy or compact disk. The author should send the revised manuscript, along with printed high-resolution color or black and white photos, copyright transfer letter, and responses to the reviewers by courier (such as EMS/DHL).

Editorial Office

World Journal of Stem Cells

Editorial Department: Room 903, Building D,

Ocean International Center,

No. 62 Dongsihuan Zhonglu,

Chaoyang District, Beijing 100025, China

E-mail: wjsc@wjgnet.com

<http://www.wjgnet.com>

Telephone: +86-10-85381891

Fax: +86-10-85381893

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from <http://www.wjgnet.com/1007-9327/news/10.doc>.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: <http://www.wjgnet.com/1007-9327/news/12.doc>.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJSC will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekaAlert/AAAS (<http://www.eurekaalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

Publication fee

Authors of accepted articles must pay a publication fee.

EDITORIAL, TOPIC HIGHLIGHTS, BOOK REVIEWS and LETTERS TO THE EDITOR are published free of charge.